[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Correction
September 20, 2006

Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation: A Randomized Controlled Trial—Correction

JAMA. 2006;296(11):1355. doi:10.1001/jama.296.11.1355

Additional Study Group Member: In the Original Contribution entitled “Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation: A Randomized Controlled Trial” published in the July 5, 2006, issue of JAMA (2006;296:56-63), the following name should appear. On page 63, under the Varenicline Phase 3 Study Group, “Raymond Niaura, PhD, Transdisciplinary Research, Butler Hospital, Providence, RI” should appear at the end of the list.

×